{
    "clinical_study": {
        "@rank": "109096", 
        "arm_group": [
            {
                "arm_group_label": "Morphine:guanfacine", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be randomized into 1 of the following 5 treatment groups:\nmorphine: placebo\nmorphine: guanfacine (1mg)\nmorphine: guanfacine (2mg)\nplacebo: guanfacine (2mg)\nplacebo: placebo\nSubjects who are randomized into the guanfacine:morphine groups will be compared to the placebo-mixed or placebo only groups."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be randomized into 1 of the following 5 treatment groups:\nmorphine: placebo\nmorphine: guanfacine (1mg)\nmorphine: guanfacine (2mg)\nplacebo: guanfacine (2mg)\nplacebo: placebo\nSubjects who are randomized into the guanfacine:morphine groups will be compared to the placebo-mixed or placebo only groups."
            }
        ], 
        "brief_summary": {
            "textblock": "Dual medication (guanfacine and morphine) as a standard treatment for chronic pain."
        }, 
        "brief_title": "Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Pain", 
        "condition_browse": {
            "mesh_term": "Hyperalgesia"
        }, 
        "detailed_description": {
            "textblock": "This aim proposes that guanfacine would be a useful drug to deter opioid-induced\n      hyperalgesia (OIH) when combined with an opioid (morphine) in chronic pain management."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  18-65 years old\n\n          -  Chronic neck or back pain condition for at least 6 months\n\n          -  VAS score of 4-8\n\n          -  Has not taken an opioid for the last 6 months\n\n          -  Has not taken guanfacine (or other alpha-2AR agonists) for the last 6 months\n\n        Exclusion Criteria\n\n          -  Sensory deficits at site of QST, such as peripheral neuropathy\n\n          -  Allergic to or has had a severe adverse reaction to study medication (i.e. opioids,\n             guanfacine, lactose, vitamin B2 a.k.a. riboflavin)\n\n          -  Cannot tolerate study drugs' maximum doses\n\n          -  Takes vitamin B2 > 1.6mg/day during the study\n\n          -  Pregnant or breastfeeding\n\n          -  Pending litigation\n\n          -  Diagnosed with Raynaud's syndrome\n\n          -  Has other chronic pain conditions such as fibromyalgia or joint osteoarthritis that\n             are predominant over back and neck pain with regard to its intensity (VAS)\n\n          -  Has known pre-existing cardiovascular disease (i.e. arrhythmia - prolonged QT\n             interval > 440ms), cerebrovascular disease, hepatic or renal impairment, CNS\n             condition, metabolic condition, or history of syncope\n\n          -  Hypotension (SBP < 90 mmHg and DBP < 60 mmHg for female or SBP < 100 mmHg and DBP <\n             60 mmHg for male; measured while in a sitting position) or bradycardia (resting heart\n             rate < 60 bpm)\n\n          -  Subjects are on antihypertensive drugs (e.g., a beta-blocker) that result in\n             hypotension and/or bradycardia as defined above\n\n          -  Tests positive for non-study opioids, illicit drugs, marijuana, or non-prescribed\n             drugs\n\n          -  Major psychiatric disorders that required hospitalization in the past 6 months such\n             as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic\n             disorders\n\n          -  Currently in a treatment program for alcohol or drug abuse, or currently on methadone\n             or buprenorphine (i.e. suboxone, subutex) for treatment of addiction, or stimulants\n             for treatment of ADHD\n\n          -  History of substance or alcohol abuse (meets DSM IV criteria) per medical record or\n             subject admission\n\n          -  Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers\n             including, but are not limited to, valproic acid, macrolide antibiotics, antifungal\n             drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel\n             blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs\n\n          -  Subjects are on medications that are ligands for alpha2-adrenergic receptors\n             including antipsychotic drugs (e.g. clozapine) and tricyclic or tetracyclic\n             antidepressants (e.g. imipramine, mirtazapine, mianserin).  Any medications taken by\n             a subject at the enrollment will be reviewed regarding their compatibility with\n             guanfacine and morphine as well as possible confounding side effects.  In addition,\n             subjects will be warned of side effects of morphine such as sedation, respiratory\n             depression at the enrollment.  Subjects will be allowed to take non-opioid pain\n             medications except for gabapentinoids and amitriptyline/nortriptyline as far as such\n             medications do not have incompatibility with morphine and guanfacine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01681264", 
            "org_study_id": "2013P-001510"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Morphine:guanfacine", 
                    "Placebo"
                ], 
                "description": "Subjects will be randomized into 1 of the following 5 treatment groups:\nmorphine: placebo\nmorphine: guanfacine (1mg)\nmorphine: guanfacine (2mg)\nplacebo: guanfacine (2mg)\nplacebo: placebo\nTo compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).", 
                "intervention_name": "Guanfacine", 
                "intervention_type": "Drug", 
                "other_name": "Tenex, Intuniv"
            }, 
            {
                "arm_group_label": [
                    "Morphine:guanfacine", 
                    "Placebo"
                ], 
                "description": "Subjects will be randomized into 1 of the following 5 treatment groups:\nmorphine: placebo\nmorphine: guanfacine (1mg)\nmorphine: guanfacine (2mg)\nplacebo: guanfacine (2mg)\nplacebo: placebo\nTo compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug", 
                "other_name": "MS Contin, MS IR"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subjects will be randomized into 1 of the following 5 treatment groups:\nmorphine: placebo\nmorphine: guanfacine (1mg)\nmorphine: guanfacine (2mg)\nplacebo: guanfacine (2mg)\nplacebo: placebo\nTo compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 12 weeks of drug treatment (combination or placebo).", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo, sugar pill"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Analgesics, Opioid", 
                "Guanfacine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pain", 
            "Pain Management"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "Center for Translational Pain Research", 
            "url": "http://www2.massgeneral.org/painresearch/translational.html"
        }, 
        "location": {
            "contact": {
                "email": "tvo3@partners.org", 
                "last_name": "Trang T Vo, B.A.", 
                "phone": "617-724-6102"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Center for Translational Pain Research"
            }, 
            "investigator": {
                "last_name": "Jianren Mao, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance", 
        "overall_contact": {
            "email": "tvo3@partners.org", 
            "last_name": "Trang T Vo, B.A.", 
            "phone": "617-724-6102"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Jianren Mao, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Quantitative Sensory Testing (QST) results will be used to compare the 5 treatment groups.", 
            "measure": "Quantitative Sensory Testing (QST)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01681264"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Jianren Mao, MD, PhD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will be measured for their heat pain threshold using Quantitative Sensory Testing (QST).  The testing will be done at 5 of the 6 visits.", 
                "measure": "Heat Pain Threshold", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Subjects will be measured for their heat pain tolerance using Quantitative Sensory Testing (QST).  The testing will be done at 5 of the 6 visits.", 
                "measure": "Heat Pain Tolerance", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Subjects will be measured for their temporal pain summation using Quantitative Sensory Testing (QST).  The testing will be done at 5 of the 6 visits.", 
                "measure": "Temporal Pain Summation", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Subjects will be measured for their Diffuse Noxious Inhibitory Control (DNIC).  The testing will be done at 5 of the 6 visits.", 
                "measure": "Detecting Diffuse Noxious Inhibitory Control (DNIC)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Subjects will be measured for their heat sensation using Quantitative Sensory Testing (QST).  The testing will be done at 5 of the 6 visits.", 
                "measure": "Heat Sensation", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institutes of Health (NIH)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}